Correction to: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

Table 2 Mean Hb levels (g/dL) and mean change in hemoglobin from Baseline to EOC – Dialysis, ITT Population (N = 126)

Statistics	ITT Population (N = 126)		PP Population (N = 93)
Statistics	Darbepoetin alfa (n = 63)	Erythropoietin alfa (n = 63)	Darbepoetin alfa (n = 47)	Erythropoietin alfa (n = 46)
Baseline
n	56	53	47	46
Mean (SD)	8.39 (0.90)	8.80 (0.89)	8.39 (0.85)	8.72 (0.91)
End of first evaluation visit
n	55	51	47	46
Mean (SD)	10.20 (1.74)	10.61 (1.55)	10.33 (1.42)	10.90 (0.95)
Within group comparison
p-value#	<.0001	<.0001	<.0001	<.0001
Mean change	1.84	1.85	1.94	2.18
95% CI	[1.36–2.32]	[1.37–2.33]	[1.48–2.40]	[1.84–2.53]
Between group comparison
Mean change	−0.01		−0.24
95% CI	[−0.68–0.66]		[− 0.81–0.32]
p-value**	0.9703		0.3985

N number of subject at each visit, N total number of subjects, ITT Intent to treat, PP Per protocol
^# p-values were obtained using Paired t Test for mean (two tailed, α 0.05)
^** p-values were obtained using Unpaired t Test for mean change (two tailed, α = 0.05)
Note: Patients taken where Hb < 10 at Screening

ISSN: 1471-2369